Menin-MLL inhibitor

DRUG CLASS:

Menin-MLL inhibitor

News alerts, weekly reports and conference planners

Related drugs:

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	DSP-5336 Sensitive: B - Late Trials DSP-5336 Sensitive : B	DSP-5336 Sensitive: B - Late Trials DSP-5336 Sensitive : B
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + DS-1594 Sensitive: C2 – Inclusion Criteria venetoclax + DS-1594 Sensitive : C2	venetoclax + DS-1594 Sensitive: C2 – Inclusion Criteria venetoclax + DS-1594 Sensitive : C2
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation	Acute Myelogenous Leukemia	NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
NPM1 mutation + DNMT3A mutation + KMT2D mutation	Acute Myelogenous Leukemia	NPM1 mutation + DNMT3A mutation + KMT2D mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
SETD2 mutation + RUNX1 mutation	Acute Myelogenous Leukemia	SETD2 mutation + RUNX1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
KMT2A rearrangement + NPM1 mutation	Acute Myelogenous Leukemia	KMT2A rearrangement + NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: C3 – Early Trials revumenib Sensitive : C3	revumenib Sensitive: C3 – Early Trials revumenib Sensitive : C3
NUP98 rearrangement	Acute Myelogenous Leukemia	NUP98 rearrangement	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3	venetoclax + revumenib Sensitive: C3 – Early Trials venetoclax + revumenib Sensitive : C3
FLT3-ITD F692L + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD F692L + NPM1 mutation	Acute Myelogenous Leukemia	ponatinib + MI-503 Sensitive: D – Preclinical ponatinib + MI-503 Sensitive : D	ponatinib + MI-503 Sensitive: D – Preclinical ponatinib + MI-503 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	gilteritinib + MI-503 Sensitive: D – Preclinical gilteritinib + MI-503 Sensitive : D	gilteritinib + MI-503 Sensitive: D – Preclinical gilteritinib + MI-503 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	ARO-002 + MI-503 Sensitive: D – Preclinical ARO-002 + MI-503 Sensitive : D	ARO-002 + MI-503 Sensitive: D – Preclinical ARO-002 + MI-503 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	quizartinib + MI-503 Sensitive: D – Preclinical quizartinib + MI-503 Sensitive : D	quizartinib + MI-503 Sensitive: D – Preclinical quizartinib + MI-503 Sensitive : D
BIRC3‐MALT1 fusion	Lymphoma	BIRC3‐MALT1 fusion	Lymphoma	MI-2 Sensitive: D – Preclinical MI-2 Sensitive : D	MI-2 Sensitive: D – Preclinical MI-2 Sensitive : D
KMT2A rearrangement	Childhood B Acute Lymphoblastic Leukemia	KMT2A rearrangement	Childhood B Acute Lymphoblastic Leukemia	DS-1594 Sensitive: D – Preclinical DS-1594 Sensitive : D	DS-1594 Sensitive: D – Preclinical DS-1594 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	DS-1594 Sensitive: D – Preclinical DS-1594 Sensitive : D	DS-1594 Sensitive: D – Preclinical DS-1594 Sensitive : D
NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	revumenib Sensitive: D – Preclinical revumenib Sensitive : D	revumenib Sensitive: D – Preclinical revumenib Sensitive : D
NUP98-KDM5A fusion	Acute Myelogenous Leukemia	NUP98-KDM5A fusion	Acute Myelogenous Leukemia	VTP-50469 Sensitive: D – Preclinical VTP-50469 Sensitive : D	VTP-50469 Sensitive: D – Preclinical VTP-50469 Sensitive : D
NUP98-NSD1 fusion	Acute Myelogenous Leukemia	NUP98-NSD1 fusion	Acute Myelogenous Leukemia	VTP-50469 Sensitive: D – Preclinical VTP-50469 Sensitive : D	VTP-50469 Sensitive: D – Preclinical VTP-50469 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D

Menin-MLL inhibitor

Menin-MLL inhibitor

Associations(57)

Associations
(57)